| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.88M | 56.94M | 50.16M | 53.87M | 49.11M | 41.04M |
| Gross Profit | 13.93M | 28.55M | 20.75M | 24.34M | 25.48M | 19.57M |
| EBITDA | 3.51M | 6.49M | -5.05M | -2.07M | 2.23M | 366.00K |
| Net Income | 2.92M | 4.70M | -7.28M | -5.33M | 548.00K | 362.00K |
Balance Sheet | ||||||
| Total Assets | 30.55M | 32.34M | 26.13M | 34.31M | 35.38M | 27.59M |
| Cash, Cash Equivalents and Short-Term Investments | 10.32M | 9.79M | 2.62M | 10.12M | 9.01M | 4.69M |
| Total Debt | 5.75M | 6.11M | 7.43M | 8.60M | 9.47M | 9.60M |
| Total Liabilities | 27.01M | 28.57M | 28.04M | 29.68M | 26.28M | 20.16M |
| Stockholders Equity | 3.51M | 3.77M | -1.90M | 4.64M | 9.10M | 7.43M |
Cash Flow | ||||||
| Free Cash Flow | 7.24M | 7.00M | -6.97M | 1.08M | 4.11M | -4.96M |
| Operating Cash Flow | 7.67M | 7.39M | -6.14M | 3.96M | 6.50M | -1.68M |
| Investing Cash Flow | -435.00K | -389.00K | -836.00K | -2.87M | -2.38M | -3.17M |
| Financing Cash Flow | 193.00K | 170.00K | -527.00K | 11.00K | 207.00K | 1.20M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $188.17M | 32.16 | 15.99% | ― | 62.79% | ― | |
| ― | $95.00M | 34.13 | 185.89% | ― | 10.11% | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $136.28M | -12.57 | -57.94% | ― | ― | 11.78% | |
| ― | $182.60M | ― | -88.95% | ― | ― | -553.86% | |
| ― | $120.41M | -4.19 | -41.66% | ― | ― | -8.91% |
On October 16, 2025, Champions Oncology, Inc. held its Annual Meeting of Stockholders, where key decisions were made. The company’s seven director nominees were elected for a one-year term, and the appointment of EisnerAmper LLP as the independent registered public accounting firm was ratified. Additionally, a non-binding advisory resolution on executive compensation was approved, indicating shareholder support for the company’s leadership and strategic direction.
The most recent analyst rating on (CSBR) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Champions Oncology stock, see the CSBR Stock Forecast page.
The recent earnings call for Champions Oncology reflects a company in transition, with signs of recovery and growth tempered by ongoing challenges. The sentiment expressed during the call was one of cautious optimism, as the company reported a rebound in revenue and strong momentum in its data platform and radiopharmaceutical services. However, flat year-over-year revenue, an operating loss, and decreased gross margins highlight the hurdles that remain. Despite these challenges, the company maintains a stable financial position with a strong cash reserve and no debt.
Champions Oncology, Inc. is a global preclinical and clinical research services provider specializing in oncology R&D solutions for biopharma organizations, known for its extensive bank of patient-derived xenograft models and innovative bioanalytical platforms. In its latest earnings report for the first quarter of fiscal 2026, Champions Oncology reported a total revenue of $14 million, with an adjusted EBITDA of $60,000, marking a positive start to the fiscal year despite a slight decline in revenue compared to the previous year. Key highlights include the appointment of Rob Brainin as the new CEO, who aims to drive the company’s growth through its core services and emerging data platform, as well as a focus on scientific excellence and collaboration. Financially, the company experienced a loss from operations amounting to $527,000, primarily due to increased costs and operating expenses, including higher outsourced lab services and investments in its data licensing platform. Looking ahead, Champions Oncology’s management remains optimistic about continued revenue growth and margin improvement, supported by a strong services pipeline and increasing demand for its data offerings, positioning the company for long-term success.
The latest earnings call for Champions Oncology paints a picture of a company on the upswing, with notable achievements such as record revenue and a return to profitability. The sentiment was largely positive, buoyed by successful data licensing deals. However, the call also acknowledged ongoing challenges, including a decline in Q4 revenue and gross margin, as well as market constraints affecting the biotech and pharma sectors.